SCHEMBL31349488

SCHEMBL31349488

CC1(O)CC(n2cnc3cc(B4OC(C)(C)C(C)(C)O4)cc(C(F)F)c32)C1

nearest known ligand 0.35

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30506902 0.84 AAK1 (0.36) AAK1
SCHEMBL25314864 0.84 AAK1 (0.36) AAK1
SCHEMBL30506768 0.82 AR (0.35)
SCHEMBL25319203 0.82 AR (0.35)
SCHEMBL25924214 0.82 AR (0.35)
SCHEMBL26023925 0.80 AR (0.31)
SCHEMBL25316660 0.80 AR (0.31)
SCHEMBL30507209 0.80 AR (0.31)
SCHEMBL31349463 0.79 OPRM1 (0.31)
SCHEMBL25315214 0.77 PDGFRB (0.33) AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743078-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2026-05-20 EP disclosed
WO-2025015104-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2025-01-16 WO disclosed